Table 3.
Multivariate Cox proportional hazard regression analysis for progression-free survival (PFS) and overall survival (OS) according to post-treatment peripheral lymphocyte count.
| PFS | OS | |||
|---|---|---|---|---|
| aHR (95% CI) | p | aHR (95% CI) | p | |
| Age, year | ||||
| < 65 | 1 (reference) | 1 (reference) | ||
| 65–74 | 0.49 (0.29, 0.81) | 0.006 | 0.67 (0.39, 1.12) | 0.10 |
| ≥ 75 | 0.43 (0.24, 0.75) | 0.004 | 0.51 (0.28, 0.93) | 0.02 |
| Sex | ||||
| Male | 1 (reference) | 1 (reference) | ||
| Female | 0.93 (0.54, 1.57) | 0.87 | 0.94 (0.54, 1.64) | 0.84 |
| Smoking status | 0.49 (0.28, 0.85) | |||
| Never | 1 (reference) | 1 (reference) | ||
| Ever | 0.49 (0.28, 0.85) | 0.006 | 0.65 (0.36, 1.19) | 0.2 |
| ECOG (ref 0) | ||||
| 0 | 1 (reference) | 1 (reference) | ||
| 1 | 2.04 (1.09, 3.78) | 0.02 | 2.56 (1.24, 5.26) | 0.02 |
| ≥ 2 | 3.00 (1.53, 5.92) | 0.001 | 4.37 (2.11, 9.08) | < 0.001 |
| Histology | ||||
| Adenocarcinoma | 1 (reference) | 1 (reference) | ||
| Sqaumous cell carcinoma | 1.23 (0.64, 2.35) | 0.54 | 1.16 (0.57, 2.37) | 0.57 |
| Other NSCLC | 1.52 (0.90, 2.56) | 0.18 | 2 (1.18, 3.40) | 0.01 |
| EGFR activating mutation | 2.78 (1.54, 5.01) | 0.001 | 1.86 (0.97, 3.61) | 0.07 |
| PD-L1 expression (≥ 1%) | 0.48 (0.31, 0.78) | 0.004 | 0.55 (0.34, 0.9) | 0.01 |
|
Post-treatment PLC, Quartile [min–max] | ||||
| 1 [208.6–1178.6] | 1 (reference) | 1 (reference) | ||
| 2 [1181–1676.7] | 0.61 (0.35, 1.06) | 0.082 | 0.59 (0.32, 1.06) | 0.09 |
| 3 [1686.7–2180] | 0.40 (0.22, 0.73) | 0.005 | 0.29 (0.15, 0.57) | < 0.001 |
| 4 [2186.9–5141.7] | 0.28 (0.16, 0.52) | < 0.001 | 0.35 (0.19, 0.65) | < 0.001 |
| P for trend | 0.001 | 0.005 | ||
PFS, progression-free survival; OS, overall survival; aHR, adjusted hazard ratio; CI, confidence interval; PLC, peripheral lymphocyte count.